Quick Answer
Coya Therapeutics, Inc. reported Diluted EPS of $1.27 per share (loss) for fiscal year 2025.
Coya Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.27 | -29.6% |
| 2024 | -$0.98 | -24.1% |
| 2023 | -$0.79 | +83.3% |
| 2022 | -$4.73 | -150.3% |
| 2021 | -$1.89 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | +50.0% | +63.9% |
| June 30, 2025 | -$0.36 | -89.5% | +18.2% |
| March 31, 2025 | -$0.44 | -25.7% | -69.2% |
| September 30, 2024 | -$0.26 | +23.5% | -36.8% |
| June 30, 2024 | -$0.19 | +38.7% | +45.7% |
| March 31, 2024 | -$0.35 | -25.0% | -2.9% |
| September 30, 2023 | -$0.34 | +78.1% | -9.7% |
| June 30, 2023 | -$0.31 | +76.5% | -10.7% |
- Coya Therapeutics, Inc. showed a decrease of -29.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Coya Therapeutics, Inc.’s diluted eps has grown by 32.8% (from $1.89 per share (loss) to $1.27 per share (loss)).
- The most recent figure is from Coya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: